• Investors
  • News
  • Careers
  • Contact
Vaxart Home Button
  • Global Need
    • Vaccines
    • History & Impact
  • Our Solution
    • Oral Vaccines
    • Technology
    • Vaccine Advantages
    • Platform Advantages
  • Pipeline
    • Research & Development
    • Norovirus
    • Influenza
    • RSV
    • HPV
  • About Us
    • Our Mission
    • Our Team
    • Careers
    • Contact
    • Compliance
  • Investors
  • News
  • Careers
  • Contact

Research & Development

Vaxart has a development program focused on prophylactic and therapeutic vaccines in multiple indications.

Pipeline

Product Candidate
Phase
Milestones
Prophylactic Vaccines
Norovirus
Phase 2
  • Bivalent Study Complete
Influenza
Phase 2
  • License and/or partner
Respiratory Syncytial Virus (RSV)
Preclinical
  • License and/or partner
Covid-19
Phase 2
  • Complete Phase 2
  • Prophylactic Vaccines
    Norovirus
    Phase 2
    Influenza
    Phase 2
    Respiratory Syncytial Virus (RSV)
    Preclinical
    Covid-19
    Phase 2
Therapeutic Vaccines
Human papillomavirus (HPV)
Preclinical vaccine (dysplasia/cancer)
  • Pre-IND
  • Therapeutic Vaccines
    Human papillomavirus (HPV)
    Preclinical vaccine (dysplasia/cancer)

See our Current Pipeline

 

We are currently focusing on the development of our coronavirus vaccine. We are actively looking for a partner for our influenza vaccine program. All Vaxart vaccine trials are conducted by U.S.-based contract research organizations under good clinical practices (GCP). Vaxart vaccines are manufactured under good manufacturing practices (GMP) in the U.S. The Vaxart vaccine is administered as a convenient enteric-coated tablet.

Reference: Vaxart data on file.

Presentations

 

Moving the needle: blocking transmission and boosting existing vaccines by oral tablet vaccination

Dr. Sean N. Tucker | Vaxart | World Vaccine Congress 2022

 

© 2022 Vaxart, Inc., All rights reserved. Terms of UsePrivacy Policy